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Locoregional Failure Analysis in Head-and-Neck Cancer 
Patients Treated with IMRT 
Gabriela Studer, Urs M. Luetolf, Christoph Glanzmann1 
Purpose: Analysis of locoregional failure in head-and-neck cancer (HNC) following intensity-modulated radiation therapy (IMRT), 
with focus on the location of locoregional failures in relation to the chosen planning target volumes (PTVs) and dose distribu-
tions.
Patients and Methods: Between January 2002 and May 2006, 280 HNC patients were subjected to IMRT at the authors’ institu-
tion. Mean follow-up was 23.2 months (3–59.3 months). Definitive IMRT was performed in 75% of all patients. In 71%, simulta-
neous cisplatin-based chemotherapy was given. 70% of patients presented with T3/4, T1–2 N2c/3 or recurred disease. Locore-
gional failure patterns were analyzed.
Results: 2-year local, nodal, distant, disease-free, and overall survival rates were 80%, 87%, 87%, 73%, and 82%, respectively. 
46 local (16%) and 31 nodal (11%) failures have been observed so far. Local tumor persistence was seen in 23/46 cases (50%), 
and nodal persistence in 12/31 (39%), respectively. One marginal local failure developed in a patient referred for a recurred oral 
cavity tumor. Three nodal failures developed outside the PTVs at unexpected locations. All other failures have been confirmed “in 
field”. No failure occurred in level Ib or upper level II. Local failure occurred mainly following definitive IMRT for large tumors, 
nodal failure only in nodally positive patients with nodal high-risk features. 
Conclusion: The dose-volume concept as used here has shown to be adequate, with disease failure developing at the site of the 
initial gross tumor manifestation inside the boost volume. 
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Strahlenther Onkol 2007;183:417–23 
DOI 10.1007/s00066-007-1663-8 
Analyse des lokoregionalen Tumorversagens nach IMRT bei Patienten mit Kopf-Hals-Tumoren 
Ziel: Analyse des lokoregionalen Tumorversagens nach intensitätsmodulierter Radiotherapie (IMRT), mit Fokus auf den Ort des 
Versagens in Bezug auf die konturierten Volumina bzw. die Dosisverteilung.
Patienten und Methodik: Zwischen Januar 2002 und Mai 2006 wurden an der eigenen radioonkologischen Klinik 280 Patienten 
mit Kopf-Hals-Tumoren einer IMRT unterzogen. Die mittlere Beobachtungszeit beläuft sich auf 23,2 Monate (3–59,3 Monate). 
Bei 75% der Patienten wurde eine definitive IMRT durchgeführt. 71% der Patienten erhielten eine simultane Chemotherapie mit 
Cisplatin. 70% wurden mit fortgeschrittenen Stadien T3/4, T1–2 N2c/3 oder einem Rezidiv zugewiesen (Tabelle 2). Das lokoregio-
nale Ereignismuster wurde analysiert.
Ergebnisse: Die Lokal-, Nodal- und Fernkontrollraten nach 2 Jahren beliefen sich auf 80%, 87% und 87%, die krankheitsfreie bzw. 
Gesamtüberlebensrate betrug 73% und 82% (Tabelle 4). 46 Fälle (16%) lokalen und 31 (11%) nodalen Versagens wurden bislang 
festgestellt, die in 23/46 Fällen (50%) einer lokalen und in 12/31 Fällen (39%) einer nodalen Tumorpersistenz entsprachen. Nur 
ein Patient mit einem bereits rezidivierten Mundhöhlentumor entwickelte ein Feldrandrezidiv (Tabelle 1). Dreimal fand sich ein 
nodales Versagen außerhalb der Planungszielvolumina an unerwarteten Lokalisationen. Alle anderen Fälle von Versagen konnten 
als „im Feld“ befindlich bestätigt werden. Kein Versagen wurde im Lymphknotenlevel I oder kranial im Level II gefunden (Tabellen 
5 und 6). Lokales Versagen erfolgte hauptsächlich bei primär bestrahlten Patienten mit großem Tumorvolumen (Abbildungen 1 
und 2a); nodales Versagen fand sich ausschließlich bei initial nodal positiven Patienten mit nodalen Risikofaktoren (Tabelle 3, 
Abbildung 2b).
Schlussfolgerung: Das hier verwendete Dosis-Volumen-Konzept erwies sich als adäquat, da der Großteil der Rückfälle am Ort der 
initialen Tumormanifestation, innerhalb des Boostvolumens, auftrat.
Schlüsselwörter:  Lokoregionale Tumorkontrolle · Outcome bei Kopf-Hals-Tumoren · Feldrandversagen bei IMRT 
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Introduction 
Increasing numbers of reports on intensity-modulated radia-
tion therapy (IMRT) in head-and-neck cancer (HNC) are avail-
able, most of them on oropharyngeal [4, 7, 8, 21, 29] and naso-
pharyngeal tumors [13, 16, 17, 28]. To date, there is no generally 
accepted standard fractionation or technique, and for several 
HNC subsites like hypopharynx, larynx, or oral cavity, IMRT 
reports are still scant [25] or missing. Encouraging results have 
been reached at several IMRT centers, by/despite using differ-
ent IMRT fractionation schedules and technical solutions like 
dose painting, serial dose application, pure IMRT, or IMRT 
combined with conventional three-dimensional conformal ra-
diation therapy (3D-CRT). Published data are concordant with 
regard to a tendency toward improved locoregional disease 
control, and confirm a better normal-tissue tolerance compared 
to 3D-CRT. However, results from prospective randomized 
multicenter phase III trials are not yet available, outcome data 
of concurrent chemotherapy and IMRT have been published 
for only limited numbers of patients (mostly those with naso-
pharyngeal cancer), and the characteristic advantage of IMRT, 
a more conformal dose distribution, bares an increased risk of 
marginal miss [19]. Meanwhile, several anatomic atlases and 
guidelines are available, providing support in outlining lym-
phatic pathways in an appropriate, risk-adjusted, standardized 
way (RTOG website, www.rtog.org) [10, 18, 20]. 
Despite a wide variability of IMRT schedules and plan-
ning target volume (PTV) definitions, the majority of locore-
gional failures – as far as published – are reported to occur at 
the site of former gross tumor volume (GTV), inside the con-
tour defining the high-dose planning target volume (PTV1), 
respectively (Table 1, [3, 5, 6, 8, 17, 29]). Consequent follow-up 
of treated patients and analysis of observed failure patterns 
are of high importance for every center performing IMRT, in 
order to realize institutional clinical quality assurance and fur-
ther progress in IMRT. 
This study aimed to evaluate the locoregional failure pro-
file of our single-institution HNC IMRT cohort. 
Patients and Methods 
Patients 
Demographic and tumor characteristics of 280 patients treat-
ed between January 2002 and May 2006 are listed in Table 2. 
The histopathologic diagnoses included 246 squamous cell 
carcinomas, ten adenocarcinomas, 13 lymphoepithelioid tu-
mors (nasopharyngeal, Schmincke type), three sarcomas, two 
melanomas, two neuroendocrine tumors, two undifferentiat-
ed spindle cell tumors, and two undifferentiated carcinomas 
(NOS). 
Cisplatin-based chemotherapy was given to 229 patients 
(40 mg cisplatin/m2/IMRT week); 51 patients did not undergo 
chemotherapy for several reasons: age > 76 years and/or co-
morbidity (n = 25), parotid tumors (n = 4), patient’s prefer-
ence (n = 5); also included into this subgroup were 17 patients 
who tolerated only one to two cisplatin cycles (subjective, or 
rarely medical reasons). 
Methods 
Locoregional failures were analyzed with focus on their loca-
tion in relation to the contoured volumes and the dose distri-
bution of treatment plans, respectively (by two different in-
vestigators [G.S., C.G.]). Failures were defined as follows: 
•  “in-field failure”: ≥ 95% of the recurred tumor volume inside 
the PTV1 (high-dose PTV), 
•  “marginal failure”: 20% to < 95% of the recurred tumor in-
side the PTV1, 
•  “outside”: < 20% of the recurred tumor volume within the 
95% isodose of the PTV1. 
In addition, the impact of diagnosis (subsites, Table 4), 
treatment sequence, UICC TN staging (Figure 1), GTVs (Fig-
ures 2a and 2b), and nodal risk factors has been assessed. 
For nodal risk feature assessment, 
we used the same histopathologic risk 
features as defined by Ang et al. [2] for 
dissected nodes. This classification has 
been adjusted for the nonoperated sub-
group. The risk factors “extracapsular 
extension”, “resection status” (R0–2), 
and “perineural invasion” cannot be 
used in nonoperated individuals, and 
have been replaced by two additional 
adverse factors, “central node necrosis”, 
and “recurrence”. Risk levels have been 
defined as follows, based on the risk fac-
tors listed in Table 3: 
•  “low risk”: no adverse factor, 
•  “intermediate risk”: only one adverse 
factor, 
•  “high risk”: two or more adverse fac-
tors. 
Table 1. Selected publications on locoregional failure analysis in intensity-modulated radiation 
therapy. PTV1: high-dose planning target volume. 
Tabelle 1. Ausgewählte Publikationen zur lokoregionalen Versagensanalyse nach intensitäts-
modulierter Radiotherapy. PTV1: Hochdosis-Planungszielvolumen. 
    Site of locoregional failure
Authors  Year Patients Failuresa Inside PTV1 Marginal Out of field
[reference]  (n) (n) (n) (n) (n)
Dawson et al. [6] 2000      58   16   10   2   4
Lee et al. [17] 2003    150   10   10   0   0
Chao et al. [5] 2003    165   17     9   3b   5
Eisbruch et al. [8] 2004    133   21   17   4   0
Bussels et al. [3] 2004      72   20   15   5c   0
Yao et al. [29] 2005    151   11   10   1   0
Own series 2006    280   77   73   1   3
Patients [n (%)]  1,009 172 144 (84) 16 (9) 12 (7)
a local and/or nodal events; b marginal to clinical target volume CTV1 or CTV2; c the bulky mass inside the PTV1, 
but extending outside  
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Contouring of GTV and PTV1 
When defining the GTV and PTV, we have always taken the 
findings in diagnostic imaging (computed tomography [CT] 
and/or magnetic resonance imaging [MRI], and/or fused posi-
tron emission tomography-CT (PET-CT, in 97% [11]), as well 
as clinical examination and the patterns of spread of the tumor 
into account. In postoperative cases, the pretreatment GTV 
was drawn in the planning CT.
In definitive as well as postoperative IMRT, the PTV1 in-
cluded the GTV of the primary and of macroscopic nodal dis-
ease with a margin of at least 1.0–1.5 cm in all directions.
Contouring of the Elective Nodal Pathways (PTV2) 
The volume definitions have basically been performed using 
the RTOG lymph node atlas (www.rtog.org). The following is 
a general description of our approach toward the elective nod-
al pathways’ volume definition: 
•  for nasopharyngeal tumors, levels II–V, the retropharyngeal 
nodes, and the supraclavicular nodes were routinely cov-
ered. When no submandibular nodes were involved, levels 
Ia and Ib were not included. 
•  for oropharyngeal tumors without extension into the oral 
cavity, levels II–V and supraclavicular nodes were covered. 
When no submandibular nodes were involved, levels Ia and 
Ib were not routinely included, although often irradiated 
due to their vicinity to the GTV and PTV1. In lateral oro-
pharyngeal tumors with contralateral N0, the upper part of 
the contralateral level II was not covered. In early unilateral 
disease, the contralateral neck was not treated; in oral cavity 
tumors, level I was included. 
•  in hypopharyngeal and laryngeal tumors, levels II–VI and 
supraclavicular nodes were included, without level Ia/b and 
the upper part of level II in most cases. 
In comparison with the RTOG recommendations, no 
routine coverage of level I nodes was performed but in oral 
cavity tumors. The ventral level Ib and the cranial part of 
level II were restrictively treated. PTV2 coverage of the cra-
nial part of level II was divided into three levels: up to the 
skull base, up to the tip of the dens axis (height of first cervi-
cal vertebral body, C1), and up to the base of the dens, re-
spectively. 
IMRT Schedules 
Simultaneously integrated boost (SIB) was performed in all 
cases. Details to the use of SIB, planning computerized to-
mography, planning systems, and linear accelerator used are 
reported elsewhere [24]. The following schedules were used 
(five fractions per week each): 
•  66 Gy (PTV1, 2.2 Gy/fraction) and 54 Gy (PTV2, 1.8 Gy/
fraction) in 30 fractions (n = 40), 
Table 2. Demographic and tumor characteristics of the assessed head- 
and-neck IMRT cohort. CT: computed tomography; FU: follow-up; IMRT: 
intensity-modulated radiation therapy; NA: not available.  
Tabelle 2. Demographische und tumorbezogene Charakteristika der 
untersuchten Kohorte mit Kopf-Hals-IMRT. CT: Computertomogra-
phie; FU: Nachbeobachtungszeit; IMRT: intensitätsmodulierte Radio-
therapie; NA: nicht angebbar. 
Factors Definitive IMRT Postoperative IMRT
Patients [(n%)] 210 (75) 70 (25)
Gender (male : female) 165 : 45 58 : 12
Age (years) 60 (21–87) 60 (38–85)
Diagnosis
• Oropharynx 82 23
• Oral cavity 25 19
• Hypopharynx 40  4
• Larynx 24  6
• Nasopharynx 24  0
• Sinus  8 13
• Parotid  0  4
• Others  7  1
T-stages (n)
• Tx  0  1
• T1 15 15
• T2 69 17
• T3 41  5
• T4 68 19
• Recurrence 17 13
N-stages (n)
• N0 37 23
• N1 27  7
• N2a/b 60 33
• N2c 66  4
• N3  5  3
• Nodal recurrences 15  0
Concomitant CT [(n%)] 179 (85%) 50 (71%)
Total tumor volume [(n%)]
• ≤ 15 cm3  42 (20) NA
• > 15–70 cm3 124 (59) NA
• > 70 cm3  44 (23) NA
Mean FU (months) 23.6 (3–59.3) 22.3 (5–50.5)
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Figure 1. Actuarial 2-year local control according to the T-stage. 
Abbildung 1. 2-Jahres-Lokalkontrollraten in Abhängigkeit vom T-Sta-
dium. 
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•  69.6 Gy (PTV1, 2.11 Gy/fraction) and 54 Gy (PTV2, 1.64 
Gy/fraction) in 33 fractions (n = 155),
•  66–70 Gy (PTV1, 2.0 Gy/fraction) and 54–56 Gy (PTV2, 
1.8–1.6 Gy/fraction) in 33–35 fractions (n = 78).
In seven patients, slightly different schedules were used.
Initially, the regimen with 2.2 Gy/fraction was used, ac-
cording to the RTOG H-0022 pilot series by A. Eisbruch. The 
dose per session was then changed to a slightly lower SIB dose 
of 2.11 Gy, as described and analyzed elsewhere [24]. The 
schedule with 2.0 Gy/fraction was used in postoperative pa-
tients, and in definitively irradiated patients with tumors close 
to central nervous structures (CNS), in order to keep dose/
fraction to the CNS ≤ 2.0 Gy, and the total dose ≤ 70 Gy. 
Statistics 
Actuarial survival data were calculated using Kaplan-Meier 
curves and log-rank tests implemented in StatView® (Version 
4.5). p-values < 0.05 were considered significant. 
Results 
46 local (LFs, 16%) and 31 nodal failures (NFs, 11%) occurred 
in 59/280 patients (21%). Distant failures (DFs) developed in 
25 (9%), LFs and NFs in 18 (6%), LFs and DFs in six (2%), 
NFs and DFs in three (1%), and locoregional and DFs in four 
patients (1.5%), respectively. 90% of LFs were diagnosed in 
the first 12 months (range 0–29 months), 90% of the NFs in the 
first 8–9 months (range 0–31 months), and 90% of the DFs in 
the first 12 months (range 0–34 months) after treatment, re-
spectively. Actuarial 2-year survival rates of the entire popula-
tion are shown in Table 4. 
Patterns of Failure 
Local failures (LF) were found “in field” in 45 of 46 cases. One 
patient presented with a “marginal” failure of a recurred oral 
cavity cancer. Local persistence was observed in 23/46 cases 
(50%). 
4/46 LFs occurred in postoperative IMRT (6%, [22]), 42 
in the 210 definitively irradiated patients (20%). The postop-
erative subgroup resulted in 94% 2-year local control versus 
77% in definitive IMRT (p = 0.004). 
Patients with a primary GTV of > 70 cm3 had a > 40% 
(14/34) risk for local progression, while only 5/67 patients with 
tumors ≤ 15 cm3 failed [26] (Figures 2a and 2b). There was a 
2-year disease control rate of > 90% in small tumors up to 15 
cm3, versus ~50% in tumors > 70 cm3. 
Subsite analysis showed poorest local outcome in pri-
marily irradiated oral cavity cancer with 33% local control 
versus 85% local control in operated patients (p < 0.001) 
[12]. 
T-stage distribution in failed primaries was as follows: 
1/30 T1, 10/86 T2, 8/46 T3, 20/87 T4, and 7/30 patients with a 
recurrence, respectively (Figure 1; p = 0.1). 
0
0.2
0.4
0.6
0.8
0.2
0.4
0.6
0.8
1
C
um
ul
at
iv
e 
su
rv
iv
al
0 10 20 30 40 50 60
months
Primary GTV ≤ 15 cm3 
Primary GTV 16−70 cm3 
Primary GTV >70 cm3 
Local control p  <0.001
0
1
C
um
ul
at
iv
e 
su
rv
iv
al
0 10 20 30 40 50 60
months
Total GTV ≤ 15 cm3 
Total GTV 16−70 cm3 
Total GTV >70 cm3 
Nodal control
p < 0.001
Figures 2a and 2b. Volumetric staging system (VS). a) Actuarial 2-year local control rates, based on the primary gross tumor volume (GTV) in de-
finitive IMRT. b) Actuarial 2-year nodal control rates, based on the total GTV. None of the nodally negative patients failed.
Abbildungen 2a und 2b. Volumetrisches Staging-System (VS). a) 2-Jahres-Lokalkontrollraten, basierend auf dem makroskopischen Primärtumor-
volumen (GTV) bei Patienten mit definitiver IMRT. b) 2-Jahres-Nodalkontrollraten, basierend auf dem totalen GTV. Bei den initial nodal negativen 
Patienten ereigneten sich keine Fälle von nodalem Versagen.
Table 3. Adverse nodal risk factors used as prognostic indicators for 
nodal failure in nonoperated patients. OCC: oral cavity cancer. 
Tabelle 3. Angewandte ungünstige nodale Risikofaktoren als prognos-
tische Indikatoren für die nodale Versagenswahrscheinlichkeit bei 
nichtoperierten Patienten. OCC: Mundhöhlenkarzinome. 
Adverse factors n/31 nodal failures 
> 1 nodal group 23
≥ 2 positive lymph nodes 29
> 3 cm lymph node   9
OCC   9
Central necrosis 21
Recurrence   5
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Local control, disease-free and overall survival rates in pa-
tients who underwent three to seven cycles of cisplatin versus 
zero to two cycles differed significantly, with 85% versus 62% 
(p = 0.0003), 78% versus 60% (p = 0.001), 
and 86% versus 70% (p = 0.004), respec-
tively. There was no significant differ-
ence in nodal and distant control with 
90% versus 82% (p = 0.16) and 90% ver-
sus 85% (p = 0.25).
Nodal failure (NF) was observed in-
side the PTV1 in 26/31 cases, and inside 
the PTV2 in two cases. Three times, 
nodal recurrence developed outside of 
PTV1/2, at atypical locations. Persis-
tence was found in 12/32 cases (39%). 
Five NFs occurred following postop-
erative (7%), 26 following definitive 
IMRT (12%; p = 0.14). The N-stage dis-
tribution in NF patients was 4/34 N1, 9/93 
N2a,b, 12/70 N2c, 2/8 N3, and 4/15 pa-
tients treated for recurrence, respectively 
(p = 0.02). All patients with N0 status (n = 
60) remained nodally controlled. Of im-
portance, considering the restrictive dose 
coverage, none of the failed nodes were 
located in level I or in the cranial part of 
level II. Doses delivered to level Ib are 
shown in Table 5, and coverage of the up-
per level II in Table 6, respectively. 
Level II was contoured (PTV2, 
> 45 Gy) up to the skull base in 75 sides, 
and up to the tip of the dens (C1) in 41. 
Nine nodally negative neck sides were 
only covered up to the basis of the dens 
axis, respectively. In several nodally pos-
itive patients a neck dissection has been 
performed following IMRT (separate 
manuscript). 
Tolerance 
Acute reactions to treatment were mild 
to moderate and are described in detail 
in a former analysis [24]. Xerostomia and dysphagia rates in 
144 patients with no evidence of disease, assessed at 1 year 
post treatment, were as follows: grade 0 41% and 80%, grade 
Table 4. 2-year survival rates, analyzed according to the assessed tumor subsites. 
Tabelle 4. 2-Jahres-Überlebensraten, analysiert nach Diagnosen. 
2-year control  Oropharnyx Nasopharynx Hypopharynx Oral cavity Larynx Sinonasal All
rates (n = 105) (n = 24) (n = 44) (n = 44) (n = 30) (n = 21) (n = 268)
Local control (%) 88 77 89 60 83 82 80
Nodal control (%) 90 93 93 76 83 95 87
Distant control (%) 92 75 93 88 85 77 87
Disease-free survival (%) 81 66 80 57 71 63 73
Overall survival (%) 91 86 93 52 70 69 82
Table 5. Coverage of level Ib (distal of the submandibular gland). Hyp: hypopharyngeal carci-
noma; NPC: nasopharyngeal carcinoma; Oro: oropharyngeal carcinoma.  
Tabelle 5. Dosierung der Lymphabflussregion Ib (distal der Glandula submandibularis). Hyp: 
Hypopharynxkarzinom; NPC: Nasopharynxkarzinom; Oro: Oropharynxkarzinom.  
Diagnosis Total Ib Nodal status  Ib contoured  > 45 Gy 30–45 Gy < 30 Gy 
 (n) (n) [n (%)]
 (= 2× n patiens)
N  N0 (13)   0 (0)   0  3 10
P  48
C  N+ (35)   9 (26)   9 15 11
H  N0 (39)   5 (13)   7 18 14
y  78
p  N+ (39)   6 (15)   6 26  7
La  N0 (24)   5 (23)   5  7 12
ry  54 
nx  N+ (30)  11 (37)  14 11  5
O  N0 (68)  10 (15)  17 42  9
r 198
o  N+ (130)  80 (62)  99 27  4
Total  N0 (144)  20 (14)  29 70 45
 378 
  N+ (234) 108 (46) 128 79 27
Table 6. PTV2 coverage (> 45 Gy) of the cranial aspect of level II (cII) in oropharyngeal tumors 
(Oro). More than half of the N0 sides were only covered up to the tip or base of the dens, while 
all N+ sides were covered at least up to the tip of the dens axis. PTV: planning target volume. 
Tabelle 6. Dosisbelegung in PTV2 (> 45 Gy) im kranialen Bereich der Lymphabflussregion II (cII) 
bei Oropharynxkarzinomen (Oro). Über die Hälfte der N0-Halsseiten wurde nur bis zur Spitze 
oder Basis des Dens axis bedient, während alle N+-Seiten mindestens bis zur Höhe der Spitze 
des Dens behandelt wurden. PTV: Planungszielvolumen. 
   Upper border PTV2
Daignosis Nodal status  Skull base Tip of dens Basis of dens Level cll Total cII 
 (n) (n) (n) (n) (n) (n)
O N0 29 25 10  64
r      184
o N+  87 33  0 120
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1 35% and 13%, and grade 2 15% and 3%, respectively. Grade 
3/4 persistent late reactions (according to the EORTC/RTOG 
toxicity criteria) included four patients with xerostomia, three 
with dysphagia, one with a laryngeal fibrosis, and one with im-
paired visual function of the optic nerve that was exposed to 
70 Gy (3% persistent late-term effects). Eight of these nine 
grade 3/4 events occurred in the 229 patients who underwent 
combined radiochemotherapy. 
Treatment tolerance data related to the used radiation 
schedules (2.0 vs. 2.11 vs. 2.2 Gy/session) are published else-
where [23, 24]. 
Discussion 
This study aimed to assess the locoregional failure profile of 
our IMRT cohort, with focus on the location of the observed 
failures in relation to the PTVs. 
Our results are in concordance with reported patterns of 
failure from other centers [3, 5, 6, 8, 17, 29], describing a low 
number of marginally failed cases (~10% of all reported fail-
ures), with the majority (~83%) of relapses at the site of for-
mer GTV, inside the boost area, respectively (Table 1). This 
key information confirms PTVs have been adequately chosen. 
The variety of diagnoses and stages of the assessed cohort 
does not impair this result. PTV margin definitions as de-
scribed seem to be appropriate likewise for all assessed tumor 
entities and volumes, respectively. 
The dose-volume concept has shown to be very satisfying 
for small tumors, while larger GTVs may profit from a mild 
dose escalation. 
Most patients were subjected to combined IMRT and 
chemotherapy. Combined-modality treatment was well toler-
ated, with a G3/4 late effect rate of 3.5% [23, 24]. The little 
number of events and the unbalanced sample size of 229 pa-
tients with chemotherapy versus 51 without, however, do not 
allow reliable statistical analysis on differences in the toler-
ance of IMRT with or without chemotherapy. Similarly, the 
highly significant local control, disease-free and overall sur-
vival differences shown in favor of the combined IMRT and 
chemotherapy subgroup should be taken with caution, given 
the different, retrospectively built subgroups, with mainly co-
morbid elderly patients characterizing the IMRT-alone sub-
group. 
In definitively irradiated patients, the failure probability 
was well predicted by the tumor volume ([26], Figure 2a), the 
presence of large macroscopic nodal disease with high-risk 
features, and the diagnosis of an oral cavity cancer as statisti-
cally significant prognostic criteria. 
The outcome in the more favorable postoperative sub-
group (positive selection in terms of locoregional tumor ex-
tent) was superior compared to definitively irradiated pa-
tients [22].
The restrictive coverage of level I/upper level II (Tables 5 
and 6) eases sparing mucosal, parotid gland, and mandible 
bone tissue [1, 14, 15, 27]. None of the patients failed in these 
areas. Of 250 Ib levels not intended to treat, only 72 (19%) 
received < 30 Gy. In contrast to the upper level II, level Ib ar-
eas which had not been included into the PTV2 often received 
doses between 30–45 Gy (in 149 of 378 Ib areas, of whom only 
128 were defined as PTV2, Table 5), due to the vicinity to the 
GTV/PTV1. Together with chemotherapy, this low dose cov-
erage represents still an effective treatment of microscopic 
disease. Fletcher et al. ([9], p. 194, Table 2-17) reported a 
60–70% eradication of occult nodal neck disease following 
3,000–4,000 rads alone (50 patients), and of > 90% when 5,000 
rads were delivered (356 patients), respectively. 
Conclusion 
The dose-volume concept as described has shown to be ade-
quate, with disease failure developing at the site of large 
GTVs, inside the high-dose area in the majority of cases. This 
may indicate a need for higher doses in locally advanced tu-
mors, and planned postoperative neck dissection in N+ pa-
tients with high-risk features, in order to further improve lo-
coregional disease control. 
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